Evelo Biosciences, Inc. (EVLO)
| Market Cap | 1.17M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -82.35M |
| Shares Out | 18.98M |
| EPS (ttm) | -13.35 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 106,413 |
| Open | 0.0540 |
| Previous Close | 0.0600 |
| Day's Range | 0.0540 - 0.0671 |
| 52-Week Range | 0.0280 - 33.0000 |
| Beta | 1.74 |
| Analysts | Hold |
| Price Target | 10.00 (+16,173.39%) |
| Earnings Date | Nov 9, 2023 |
About EVLO
Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for EVLO stock is "Hold." The 12-month stock price forecast is $10.0, which is an increase of 16,173.39% from the latest price.
News
Top 5 Health Care Stocks That Are Preparing To Pump In November - Better Therapeutics (NASDAQ:BTTX), Arcutis Biotherapeutics (NASDAQ:ARQT)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Top 4 Health Care Stocks That May Rocket Higher This Month - Generation Bio (NASDAQ:GBIO), Evelo Biosciences (NASDAQ:EVLO)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Evelo Biosciences to review options after Phase 2 trial of psoriasis treatment fails to meet main goal
Evelo Biosciences Inc. EVLO, -6.73% said Tuesday it's reviewing its strategic options and exploring partnerships after a Phase 2 study of a treatment for psoriasis failed to meet its main goal. “The s...
Evelo Biosciences Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate Psoriasis
- Primary endpoint was not achieved – - Company exploring strategic alternatives and partnering opportunities for EDP1815 and its SINTAX platform - CAMBRIDGE, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- ...
Evelo Biosciences Announces Second Quarter Financial Results and Recent Business Highlights
– EDP2939 Phase 2 trial in moderate psoriasis fully enrolled with topline data expected early Q4 2023 – Completed $25.5 Million Private Placement – Restructured and reduced secured debt with Horizon T...
Moderna Co-Founder Bought Up This Embattled Biotech Stock
Flagship Pioneering, an investment vehicle helmed by Noubar Afeyan, a co-founder of Moderna and its chairman, bought $12.5 million of shares of biotech Evelo.
Evelo Biosciences Closes $25.5 Million Private Placement
Restructures and reduce s secured debt with Horizon Technology Finance Corporation Appoints two new members and decreases size of Board of Directors
Evelo Biosciences Announces $25.5 Million Private Placement
CAMBRIDGE, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving...
Evelo Biosciences Announces Reverse Stock Split Effective
– EVLO common stock expected to begin trading on a split-adjusted basis on June 30, 2023 – CAMBRIDGE, Mass., June 29, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage b...
Evelo Biosciences Provides Clinical Updates
– Topline Data from fourth cohort of EDP1815 Phase 2 trial in atopic dermatitis did not meet primary endpoint – – Company will focus on development of extracellular vesicles (EVs) – – First EV candida...
Evelo Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), (“Evelo” or the “Company”) a clinical stage biotechnology company developing a novel platform of orally del...
Evelo Biosciences to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 16, 2023
CAMBRIDGE, Mass., March 09, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolvi...
Evelo Biosciences to Participate in the Cowen 43rd Annual Health Care Conference
CAMBRIDGE, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered anti-inflammatory med...
Evelo Biosciences Reports that EDP2939, its First Oral Extracellular Vesicle Product Candidate, Commenced Dosing in a Phase 2 Psoriasis Trial
– Completed first blinded, placebo-controlled cohort in human volunteers with no safety or tolerability concerns –
Evelo Biosciences Provides Clinical and Business Updates
– Data from first three cohorts of EDP1815 Phase 2 trial in atopic dermatitis did not meet primary endpoint; unusually high placebo response rate observed – – Clear path to registration trials for EDP...
Horizon Technology Finance Provides Fourth Quarter 2022 Portfolio Update
- Horizon Platform Originates $114 Million of New Loans in Q4, Including $104 Million of New Loans for HRZN - - HRZN Grows Loan Portfolio by $262 Million in 2022 - - Horizon Platform Ends 2022 with Co...
Evelo Biosciences Announces $45 Million Loan Agreement with Horizon Technology Finance Corporation to Refinance Existing Debt
CAMBRIDGE, Mass., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on th...
Evelo Biosciences Announces Publication of Scientific Basis for SINTAX Medicines in Frontiers in Immunology
CAMBRIDGE, Mass., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX medicines, today announced the publication of a peer...
Evelo Biosciences Reports Third Quarter 2022 Financial Results and Business Highlights
- Multiple Phase 2 readouts for EDP1815 in atopic dermatitis expected in 2023; data from first three cohorts expected in early 1Q 2023 and fourth cohort in 2Q 2023 -
Evelo Biosciences to Present at the 2022 Jefferies London Healthcare Conference
CAMBRIDGE, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on t...
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Evelo Biosciences, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
NEW YORK , Nov. 7, 2022 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim ...
Evelo Biosciences Presents Biomarker Data Demonstrating Anti-inflammatory Effects of EDP1815 in Psoriasis at the 2022 European Academy of Dermatology and Venereology (EADV) Congress
CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on ...
Evelo Biosciences Announces Grant of Inducement Award
CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on ...
Evelo Biosciences to Participate in Morgan Stanley 20th Annual Global Health Care Conference
CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on ...
Evelo Biosciences Announces Succession Plan
– Simba Gill to transition to Chair of the Board of Directors –– Lord Ara Darzi will become Lead Independent Director –– Board has retained Spencer Stuart for Chief Executive Officer search –